Taking China's finest medical products
to global healthcare markets
Bridging China's medical products to the world β focused on global reimbursement market access, with full-chain, results-based overseas expansion services.
Built on Health Technology Assessment (HTA) as our core capability, we cover the full chain from evidence generation, market access & registration, to reimbursement negotiation and commercialization β turning China's manufacturing strength into global market access and commercial advantage.
A Full-Service Overseas Expansion Platform
Whether pharmaceuticals, medical devices, vaccines or digital solutions, Qiyang completes the loop from market screening to reimbursement access and local commercialization.
Pharmaceutical Overseas Services
Generic drugs into emerging-market reimbursement lists; innovative drugs into developed-country HTA systems (NICE / HAS / IQWiG). Translating commercial asks into overseas governments' goals.
Learn more βMedical Device Overseas Services
Overseas government tendering, market-access pathway analysis, health-economics-based pricing and negotiation support.
Learn more βVaccine Overseas Services
WHO Prequalification (PQ) pathway planning, vaccine health-economic assessment, and overseas government vaccine procurement support.
Learn more βDigital Platform Β· AI-driven HTA Reporting
An in-house platform that screens 233 countries with AI, builds CEA models, and auto-generates AMCP / NICE Value Dossiers.
See pricing βWhy Chinese healthcare is going global now
About 1/3 of the world's population still lacks essential medicines, and lower- and middle-income countries bear ~90% of the global disease burden. Yet Chinese pharmaceutical exports have stayed at only 1%β2% of total exports for 9 years. Global demand + Chinese capacity + policy consensus β SDG 3.8 and Universal Health Coverage are opening a historic window.
Explore the global opportunityGLOBAL OPPORTUNITY
From validated practice to scaled replication
Every stage has verifiable deliverables: government-grade projects, tenders and on-the-ground partnerships.
- 2022 Β· Starting point
Collaboration with Thailand HITAP; CEA (cost-effectiveness analysis) modelling for national reimbursement review.
- 2023β2024 Β· Saudi breakthrough
Engagement with Saudi health authorities; CEA modelling advanced to reimbursement negotiation stage.
- 2025 Β· Company established
Based in Suzhou Industrial Park; overseas partner (Riyadh) of "Chengdu Open" initiative.
- 2026 Β· Execution validated
Hong Kong subsidiary established; generic-drug partnerships signed; co-launched "AI Overseas Service Port".
Why Qiyang
Turning China's manufacturing scale into the reimbursement language of global health systems β what you need is not a better product, but a team that can open overseas reimbursement doors and execute locally.
No direct competition from the five conventional players. CRO/CDMO, regulatory consultancies, distributors, traditional consultancies and private-equity/licensing all lack end-to-end execution or demand equity transfer β Qiyang offers another option at the same decision point.
Low upfront cost Β· a results-based path overseas
Traditional consultancies deliver only a report; clients are left without an on-the-ground team. Qiyang owns the chain from access and HTA to negotiation and promotion β our revenue comes from products actually selling.
- No equity transfer: producers keep full product ownership and 40% of ex-factory supply revenue.
- Aligned incentives: paid via revenue share β Qiyang profits only when products truly reach the market.
- End-to-end execution: evidence β registration β reimbursement β commercialization.
- HTA core capability: health-economic evidence recognized by government bodies such as Thailand HITAP.
Value proposition
Compare: an in-house BD analyst costs Β₯300kβ500k/yr; a single consultancy report Β₯150kβ300k. Qiyang offers a lightweight entry from Β₯9,800 β turning "going overseas" from an idea into an executable first step at low cost.
Qiyang's team is grounded in health economics and HTA methodology β founders trained at leading universities, with specialists in health technology assessment, regulatory affairs, commercial finance and R&D/medical affairs β supported by overseas health-economics & policy experts (Harvard/MGH and LSE backgrounds) and government policy networks in Asia and the GCC.
- β Overseas HTA experts review pharmacoeconomic models & international document standards
- β European health-policy experts support pricing strategy & payer negotiation
- β Asian government health-policy network for local access support
Have a product ready for overseas markets?
Tell us about your product and goals β a Qiyang advisor will follow up within one business day.
Contact us Β· Request a quote